Diabetic Ketoacidosis (DKA) Market Report 2026

The diabetic ketoacidosis (dka) market size has grown strongly in recent years. It will grow from $3.15 billion in 2025 to $3.42 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to poor glycemic control in diabetic patients, delayed diagnosis of acute complications, limited patient awareness, dependence on hospital emergency care, rising type 1 diabetes cases.

The diabetic ketoacidosis (dka) market size is expected to see strong growth in the next few years. It will grow to $4.69 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to improved patient education, expansion of remote monitoring tools, better insulin therapy adherence, adoption of early warning systems, focus on reducing emergency admissions. Major trends in the forecast period include rising hospitalization for acute diabetes complications, increased focus on rapid diagnosis and intervention, expansion of critical care treatment protocols, growing use of continuous glucose and ketone monitoring, integration of emergency diabetes management systems.

The rising prevalence of obesity is driving the expansion of the diabetic ketoacidosis (DKA) market. Obesity is a medical condition marked by excessive accumulation of body fat that adversely affects health and increases the risk of multiple diseases. The growth in obesity rates is driven by factors such as unhealthy diets rich in processed foods, sugars, and fats, sedentary lifestyles with limited physical activity, increased screen time, and socioeconomic challenges related to access to healthy food and healthcare. Higher obesity rates raise the risk of diabetic ketoacidosis by promoting insulin resistance and the development of type 2 diabetes, which can result in poor glycemic control and subsequent DKA episodes. For instance, in March 2024, the World Health Organization, a Switzerland-based intergovernmental body, reported that nearly one in eight people globally were affected by obesity. This included about 2.5 billion adults aged 18 years and older who were overweight, of whom 890 million were living with obesity. Among adults, 43% were overweight and 16% were classified as obese, while the number of overweight children under five years of age reached 37 million. Therefore, the increasing prevalence of obesity is contributing to the growth of the diabetic ketoacidosis market.

Major companies operating in the diabetic ketoacidosis treatment market are concentrating on the development of advanced solutions such as algorithm-driven insulin dosing systems to improve treatment accuracy, patient safety, and clinical workflow efficiency. Algorithm-driven insulin dosing systems are software-based platforms that apply mathematical models and real-time patient data, including glucose trends, renal function, and estimated residual insulin, to generate personalized intravenous insulin infusion recommendations. These systems enable dynamic dose adjustments and detailed glucose trend analysis. For instance, in December 2024, Monarch Medical Technologies, a US-based health technology company specializing in inpatient glycemic management solutions, received U.S. Food and Drug Administration (FDA) 510(k) clearance for EndoTool IV 3.1. This algorithm-driven dosing solution is designed to support the management of hyperglycemic crises, including DKA and euglycemic DKA, and features real-time insulin rate recalculation, integration of renal function and estimated residual insulin, and workflow-integrated decision support. EndoTool IV 3.1 is intended to enhance insulin delivery precision, improve safety during acute metabolic emergencies, and support informed clinical decision-making.

In September 2023, Abbott Laboratories, a US-based medical device company, acquired Bigfoot Biomedical for an undisclosed amount. Through this acquisition, Abbott aims to expand its diabetes care portfolio, which already includes the widely used FreeStyle Libre continuous glucose monitoring system. Bigfoot Biomedical Inc. is a US-based company that develops medical technologies for diabetes care.

Major companies operating in the diabetic ketoacidosis (dka) market are Merck & Co. Inc., Pfizer Inc., Sanofi S.A., Bristol Myers Squibb, Novartis AG, Roche Holding AG, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., B. Braun Medical Inc., Fresenius Kabi, Merit Pharmaceutical, Oramed Pharmaceuticals Inc., ICU Medical Inc., Tonghua Dongbao Pharmaceutical Co. Ltd., Wockhardt Ltd., Biocon Limited, Baxter International Inc., Hikma Pharmaceuticals PLC, Bayer AG, Dr Reddys Laboratories, Takeda Pharmaceutical Co Ltd, AstraZeneca plc, Amgen Inc.

North America was the largest region in the diabetic ketoacidosis (DKA) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic ketoacidosis (dka) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic ketoacidosis (dka) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diabetic ketoacidosis market by increasing costs of imported insulin formulations, infusion devices, monitoring equipment, and critical care consumables. Hospitals in North America and Europe are most affected due to reliance on imported emergency care supplies, while Asia-Pacific faces higher intensive care setup costs. These tariffs raise treatment expenses. However, they also promote domestic production of insulin and critical care medical devices.

The diabetic ketoacidosis (dka) market research report is one of a series of new reports that provides diabetic ketoacidosis (dka) market statistics, including diabetic ketoacidosis (dka) industry global market size, regional shares, competitors with a diabetic ketoacidosis (dka) market share, detailed diabetic ketoacidosis (dka) market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic ketoacidosis (dka) industry. This diabetic ketoacidosis (dka) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diabetic ketoacidosis (DKA) is a serious complication of diabetes in which the body produces excessive levels of blood acids known as ketones, typically due to insufficient insulin. This condition can lead to dehydration, electrolyte imbalances, and potentially life-threatening outcomes. Diabetic ketoacidosis management is used to diagnose and control severe metabolic disturbances in diabetic patients to prevent complications such as dehydration, organ failure, and coma.

The main types of diabetic ketoacidosis include pediatric diabetic ketoacidosis and adult diabetic ketoacidosis. Pediatric DKA occurs in children and adolescents with diabetes and is often triggered by insulin deficiency, infections, or other stress-related factors. Treatment options include fluid replacement, electrolyte supplementation, insulin therapy, as well as intermediate-acting and long-acting insulin. The routes of administration include oral, parenteral, and other methods. These treatments are distributed through both online and offline channels and are utilized by end users such as hospitals, ambulatory care centers, and specialty clinics.

The diabetic ketoacidosis (DKA) market includes revenues earned by entities by providing services such as blood glucose monitoring, ketone testing, and arterial blood gas analysis and related products such as blood glucose monitors, continuous glucose monitoring (CGM) devices, syringes, insulin pens, and insulin pumps. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.